Research Antibodies Market to witness major growth in coming years

Factors such as the increasing R&D activities and expenditure in the life science industry, increasing funding for proteomics research and drug discovery, and the growing collaboration between industries and academic institutes are the key drivers of the research antibodies market.

The Research Antibodies Market is expected to reach USD 12.60 Billion by 2022 from an estimated USD 9.33 Billion in 2017, at a CAGR of 6.2% during the forecast period.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94212793

Market Segmentation:-

On the basis of product, the reagents segment accounted for the largest share of the global research antibodies market (including reagents), in 2016. This can be attributed to the fact that a large number of reagents are used in various routine assays and techniques.

Based on technology, the western blotting segment accounted for the largest share of the Research Reagents Market. Its ability to quantify as little as 0.1 nanograms of protein in a sample with high specificity makes it an indispensable tool in proteomic research; this is the key factor driving market growth.

Based on application, the proteomics segment accounted for the largest share of the Research Reagents Market. The large share of this segment is attributed to the deployment of proteomic-based approaches in biomarker detection and cancer profiling, increasing R&D expenditure, and availability of funds from various organizations.

Based on end user, the pharmaceutical & biotechnological companies segment accounted for the largest share of the Research Antibodies and Reagents Market owing to the high uptake of research-specific antibodies in the drug discovery and development process, along with the increasing use of these research tools in the ever-developing proteomics research sector.

Key Market Opportunities: -
            1 High Growth Opportunities in Emerging Markets
            2 Increasing Demand for Personalized Medicine and Protein Therapeutics
            3 Growths in Stem Cell and Neurobiology Research
            4 Increasing Focus on Biomarker Discovery

Regional Analysis:-

North America accounted for the largest share of the Research Antibodies and Reagents Market in 2016, followed by Europe. This regional segment shows significant market growth opportunities owing to the increasing research activities in the fields of proteomics and genomics, favorable government funding initiatives, and the growing focus of stakeholders on research projects.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=94212793

Top Key Players:-

The major players in the research antibodies market (including reagents) are Thermo Fisher Scientific, Inc. (U.S.), Merck Group (Germany), Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), GenScript (U.S.), PerkinElmer, Inc. (U.S.), Lonza (Switzerland), and BioLegend, Inc. (U.S.).

 

Report explores the Research Antibodies Market is expected to reach $ 12.60 Billion by 2022

Factors such as the increasing R&D activities and expenditure in the life science industry, increasing funding for proteomics research and drug discovery, and the growing collaboration between industries and academic institutes are the key drivers of the research antibodies market.

The Research Antibodies Market is expected to reach USD 12.60 Billion by 2022 from an estimated USD 9.33 Billion in 2017, at a CAGR of 6.2% during the forecast period. 

Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94212793

Based on technology, the western blotting segment accounted for the largest share of the research antibodies market. Its ability to quantify as little as 0.1 nanograms of protein in a sample with high specificity makes it an indispensable tool in proteomic research; this is the key factor driving market growth.

On the basis of product, the reagents segment accounted for the largest share of the global research antibodies market (including reagents), in 2016. This can be attributed to the fact that a large number of reagents are used in various routine assays and techniques.

Based on application, the proteomics segment accounted for the largest share of the research antibodies market. The large share of this segment is attributed to the deployment of proteomic-based approaches in biomarker detection and cancer profiling, increasing R&D expenditure, and availability of funds from various organizations.

Based on end user, the pharmaceutical & biotechnological companies segment accounted for the largest share of the research antibodies market owing to the high uptake of research-specific antibodies in the drug discovery and development process, along with the increasing use of these research tools in the ever-developing proteomics research sector.

North America accounted for the largest share of the research antibodies market in 2016, followed by Europe. 

Read More: - https://www.marketsandmarkets.com/PressReleases/research-antibodies-reagents.asp

The major players in the research antibodies market (including reagents) are Thermo Fisher Scientific, Inc. (U.S.), Merck Group , Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), GenScript (U.S.), PerkinElmer, Inc. (U.S.), Lonza (Switzerland), and BioLegend, Inc. (U.S.).

Research Antibodies & Reagents Market by Product and Technology - 2022

Factors such as the increasing R&D activities and expenditure in the life science industry, increasing funding for proteomics research and drug discovery, and the growing collaboration between industries and academic institutes are the key drivers of the research antibodies market. However, the quality concerns over research antibodies (with respect to research reproducibility), cost- and time- intensive antibody development processes, and the pricing pressures faced by prominent market players are the major challenges currently at play in the market.

The Research Antibodies Market (including reagents) is expected to reach USD 12.60 Billion by 2022 from an estimated USD 9.33 Billion in 2017, at a CAGR of 6.2% during the forecast period.

Major Market Developments

• In January 2017, Merck expanded its end-to-end bio-development centers in North America, China, and Europe to meet increasing customer demand and also to increase its manufacturing capabilities.
• In March 2016, Thermo Fisher Scientific (US) acquired Affymetrix, Inc. (US) expanding the company’s research antibody portfolio, and strengthening its leadership in the biosciences business. It also helped Thermo Fisher add new genetic analysis capabilities in the clinical and applied markets.
• In April 2016, Abcam launched a suite of immunoassay, products based on recombinant monoclonal antibody pairs used in ELISA to study secreted biomarkers by life science researchers

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownload.asp?id=94212793
On the basis of product, the reagents segment accounted for the largest share of the global research antibodies market (including reagents), in 2016. This can be attributed to the fact that a large number of reagents are used in various routine assays and techniques.
Based on technology, the western blotting segment accounted for the largest share of the research antibodies market. Its ability to quantify as little as 0.1 nanograms of protein in a sample with high specificity makes it an indispensable tool in proteomic research; this is the key factor driving market growth.

Based on application, the proteomics segment accounted for the largest share of the research antibodies market. The large share of this segment is attributed to the deployment of proteomic-based approaches in biomarker detection and cancer profiling, increasing R&D expenditure, and availability of funds from various organizations.

Based on end user, the pharmaceutical & biotechnological companies segment accounted for the largest share of the research antibodies market owing to the high uptake of research-specific antibodies in the drug discovery and development process, along with the increasing use of these research tools in the ever-developing proteomics research sector.

Know more: - https://www.marketsandmarkets.com/PressReleases/research-antibodies-reagents.asp  

Regional Analysis:-
North America accounted for the largest share of the research antibodies market in 2016, followed by Europe. This regional segment shows significant market growth opportunities owing to the increasing research activities in the fields of proteomics and genomics, favorable government funding initiatives, and the growing focus of stakeholders on research projects.

The global research antibodies market is projected to reach USD 12.60 billion by 2022, at a CAGR of 6.2%.

The global research antibodies market (including reagents) is projected to reach USD 12.60 billion by 2022 from USD 9.33 billion in 2017, at a CAGR of 6.2%. This market is consolidated in nature with the presence of many local, regional, and global players. Thermo Fisher Scientific, Inc. (U.S.), Merck Group (Germany), Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Cell Signaling Technology, Inc. (U.S.) were the major players in this market. These companies are mainly focusing on product launches, agreements, and acquisitions to strengthen their product offerings and establish a strong geographical foothold. 

Browse 187 Market Data Tables and 42 Figures spread through 279 Pages and in-depth TOC on "Research Antibodies Market".

http://www.marketsandmarkets.com/Market-Reports/research-antibodies-reagents-market-94212793.html

 Abcam plc dominated the global research antibodies market in 2016. Abcam focuses on product launches as its major growth strategy. Since 2013, the company has launched an exclusive range of research antibodies—Alexa Fluor 680/790 secondary antibodies, anti-PD-L1 primary antibodies, and Alexa Fluor 405/568/750 conjugated secondary antibodies. The company also focuses on inorganic growth strategies such as acquisitions to strengthen its position in the market. Abcam invests in the discovery of new antibody manufacturing technologies to speed up the pace of scientific research to increase their product offerings. The company’s strategic priority is to generate growth in the core reagents business by attracting new customers and establish new growth platforms.

Cell Signaling Technology, Inc. is growing at a rapid pace in this market by adopting various organic and inorganic growth strategies. In line with this, the company launched over six different types of monoclonal antibodies for tumor research in November 2015. Furthermore, between 2013 and 2015, the company has launched various primary antibodies, mainly for cancer research. CST also focuses on expanding its business globally to strengthen its position in the research antibodies market.

Thermo Fisher Scientific, Inc. is one of the leading players in the global research antibodies market in 2016. The company significantly focuses on product launches and product innovation. It also focuses on strengthening customer engagement through the provision of custom-made antibodies. Complementary acquisitions achieve the company's strategy to augment internal growth. In November 2016, the company acquired MTI-GlobalStem (U.S.), a stem cell research products firm. The increasing demand for high-quality research products, the growing proteomics and genomics research sector, and strong presence in the emerging markets are significant growth opportunities for the company to enhance its position in the research antibodies and reagents market.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownload.asp?id=94212793

The Merck Group commanded a significant share of the global research antibodies market in 2016. The company primarily focuses on product launches and expansions to expand its product offerings and increase its geographic coverage. Since 2013, the company has launched various antibodies and reagents in the research field. In January 2017, the company expanded its end-to-end biodevelopment centers in North America, China, and Europe. Merck also focuses on acquisitions & agreements as its key growth strategies. In November 2015, the company acquired Sigma-Aldrich, a leading life science company for USD 17 billion.

Becton, Dickinson and Company is another prominent player in the global research antibodies market. The company’s strong heritage of technology leadership and innovation has provided a solid foundation for the continued development of safe and cost-effective products and services. The company is concentrating on developing new products and expanding its customer reach. BD also focuses on the inorganic growth strategy of acquisitions to strengthen its product portfolio as well as its position in the market. In April 2017, it acquired C. R. Bard, Inc. (U.S.) for USD 24 billion. By acquiring CareFusion Corporation (U.S.) in March 2015, the company positioned itself as a leading player in the healthcare and life science market.

Research Antibodies Market: An Outlook to the Future Global Opportunities

The report "Research Antibodies Market by Product (Antibodies (Primary, Secondary)(Mouse, Rabbit)), Reagents), Technology (Western Blot, Flow Cytometry, Elisa, Immunoflourescence, Immunohistochemistry), Application, & End User - Global Forecast to 2022", analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.


Browse 187 Market Data Tables and 42 Figures spread through 279 Pages and in-depth TOC on "Research Antibodies Market ".
http://www.marketsandmarkets.com/Market-Reports/research-antibodies-reagents-market-94212793.html

The research antibodies market (including reagents) is expected to reach USD 12.60 Billion by 2022 from an estimated USD 9.33 Billion in 2017, at a CAGR of 6.2% during the forecast period. Factors such as the increasing R&D activities and expenditure in the life science industry, increasing funding for proteomics research and drug discovery, and the growing collaboration between industries and academic institutes are the key drivers of the research antibodies market.  

Based on application, the proteomics segment accounted for the largest share of the research antibodies market. The large share of this segment is attributed to the deployment of proteomic-based approaches in biomarker detection and cancer profiling, increasing R&D expenditure, and availability of funds from various organizations. 

 Request For Sample Report :- https://www.marketsandmarkets.com/requestsampleNew.asp?id=94212793 




On the basis of product, the reagents segment accounted for the largest share of the global research antibodies market (including reagents), in 2016. This can be attributed to the fact that a large number of reagents are used in various routine assays and techniques.



Based on technology, the western blotting segment accounted for the largest share of the research antibodies market. Its ability to quantify as little as 0.1 nanograms of protein in a sample with high specificity makes it an indispensable tool in proteomic research; this is the key factor driving market growth.
 


Based on end user, the pharmaceutical & biotechnological companies segment accounted for the largest share of the research antibodies market owing to the high uptake of research-specific antibodies in the drug discovery and development process, along with the increasing use of these research tools in the ever-developing proteomics research sector.